Figure 6. SRI-37330 rescues mice from obesity-induced diabetes.

(a) Body weight of obese, insulin resistant and diabetic male 8-week old db/db mice treated with or without oral SRI-37330 (N.S. not significant), mean ± s.e.m, n = 7–12 mice per group.

(b) Non-fasting blood glucose in db/db mice treated with or without oral SRI-37330 (F_1,107 = 23.63, *P < 0.0001), n = 7–12 mice per group.

(c)Fasting blood glucose in db/db mice treated with or without oral SRI-37330 (t₁₅ = 5.61, P < 0.0001), n = 7–10 mice per group.

(d) Fasting serum insulin in db/db mice treated with or without oral SRI-37330,(N.S.), n = 4–7 mice per group.

(e) Fasting serum glucagon in SRI-37330 treated and untreated db/db mice, (t_8.2 = 2.35, *P = 0.0459), n = 4–8 mice per group.

(f) Basal hepatic glucose production in SRI-37330 treated and untreated db/db mice as assessed by hyperinsulinemic euglycemic clamp studies, (t₉ = 2.31, *P = 0.0460), n = 5–6 mice per group.

(g) Insulin-stimulated glucose uptake in skeletal muscle (SM; gastrocnemius) in SRI-37330 treated and untreated db/db mice (N.S.), n = 5–6 mice per group.

(h) Insulin-stimulated glucose uptake in white adipose tissue (WAT; epididymal) in SRI-37330 treated and untreated db/db mice (N.S.), n = 5–6 mice per group.

(i) Glucose infusion rates in SRI-37330 treated and untreated db/db mice (N.S.), n = 5–6 mice per group.

(j) Hepatic insulin action in SRI-37330 treated and untreated db/db mice (N.S.), n = 5–6 mice per group.

(k) Representative histological liver sections (n = 12 total sections analyzed) of SRI-37330 treated and untreated db/db mice, scale bar = 20 μm.